Management of preeclampsia & other hypertensive disorders in pregnancy

Algorithm

Purpose

This document has been developed to support hospitals and healthcare professionals to implement the recommendations made in Taonga Tuku Iho on preeclampsia, as a major contributor to provider-initiated preterm birth.

The recommendations, background, and additional information can be reviewed on the Carosika Collaborative Taonga Tuku Iho website www.bestpractice.carosikacollaborative.co.nz

Content source

This document provides a collection of management algorithms for preeclampsia and other hypertensive disorders of pregnancy in Aotearoa. They have been based on the algorithms supplied in the Te Whatu Ora – Health New Zealand 2022 'Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aotearoa New Zealand: Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa: A clinical practice guideline'.

These alogorithms include some minor adaptations that have been made in line with recommendations in Taonga Tuku Iho. All adaptations are specific to care that may impact on preterm preeclampsia and preterm birth and have been made in-line with international guidance. The rationale for differing recommendations is reported in Taonga Tuku Iho. Te Whatu Ora

Diagnosis and Treatment of Hypertension and Pre-eclampsia in Pregnancy in Aotearoa New Zealand

Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa A clinical practice guideline



Comprehensive clinical oversight of māmā/person and pēpi wellbeing is required and may override recommendations within this algorithm.

Pre-existing/chronic hypertension								Pre-eclar	psia							
(Hupertension confirmed pre-conception or before 20 weeks destation)						Hyportanako	on (dDP ic90 miniHg or aBP ic140 index to defe	mmHg) + other (form)	signs and	d sympiome						
	Pre-presentation or at first size						· Acute referral and barrely	w to obstatic team (whereal cade 42	22)							
First-line						 Consider anti-hypothensive treatment to reduce tak of severe hypothension. A for largest of s8P140-190 and d8P 80-100 mm/sp 			· .	and hypertensives		Severe	unstable pre-eclampe	sia		
Change from AUC innoces to advintative anonypersimility Assess for risk factor for one-antihypert		anonypeneos	Astves			Bpst urine PCR				- Labetald		(5ee 0				
 Indiate nation Labelatol 		Laberatol				Anness Mail growth/wellbeing (USS, unbilitial artery Doppler assessment and			 Methyldope 							
Initiate assirin at 12-10 weeks' postation		7.	Nifedpine				CTO Findualed) L (dentify and autoint some per sensitives of accessing the adapted in the					At diagnosis		*		Azzhypertensives for
< Refer to obstatric team (see referral codes 1014, 1015)			Methyldopa				The schartgenish and the tanky			south investing of BP		mmence antihyperianaive boatment, aim I		(New Yor Code # J22) for land RP 143(100 mmPin or linear		acate lowering of 8P
Educate about signs and symptoms of pre-eclampsis						Maternal monitoring			1.00.001		toider magnesium sulphate to prevent a p		primary seizure		Labetalei	
							 In providing hospital name, the obtaining learn makes a management plan for 			initially 20 mp fit bolan over 2		st urine PCR				rvitally 23 mg tv bolus over 2 mitudes
Maternal monitoring							which may include hospital admission			Repert with 40-40 mg		-eclampsia bloods				Repeat with 43-80 mg
Maintain usual schedule of antenatal visits but reonitor					BP 4-b fourly (skilig) or Chrice determination car		hight when an interval of 8 hours is acceptable) In table		Great 5 minutes Repeat with 43-80 min		me ma poer prono any coppe		and the set and Cito, a modality		43-80 mg	
EP more clusely if EP is unstable							Tates weeky pre-edergole bloots			Repeat: every 10 minutes		Maternal monitoring		Maternal monitoring -		Hopeat: every 13 minutes Maximum: 330 mg
 Ann to control hyperamatori at pro-programicy range or lower 						 Conduct coagulation studies if liver function tests are abnormal, low platelets or concerns about possible placental absupton 			Medicine"		e-to-one midwflery care rappement plan should instude		 Moord scenario analyticale 		Mitedipine"	
Fetal monitoring				A variant of		Fold another a			ind all	By 10 mg (mmediate and	Eussion	sussion with the anaesthetic and	during bolus dose, then how		Initially 13 mp (immediate releases consules)	
If monitoring raises field growth concerns:					Elements include haemolysis, al-		Palex SGA publices for management if diagnosed			Orset 33-45 minutes		marve care seams out also with obstatric d		 Respiratory rate, CQ satu 	nton.	Onset 30-45 minutes
a constant LESS, AFV, umbiling artery Deepler and CTO if indicated					Al diagnosis		 After assessment at the time of diagnosis, do not repeat USS for growth in <2 weeks 			244	(ed)	uny BP and respiratory rate		referes hourly		Hopeat: after 30-45 minutes (F reeded)
hitow SGA guidelines for management.		• At		Acute referral and transfer to strategic team (refers		Galy CTG Expansion			Maximum: 63 mp daily		east daily pro-estampsia bloods		 urms ougus (>100 mL ever 4 hours) 		Maximum: 60 mg daily	
				+ Admit 1	secondary/fartiary facility			Timing of birth		1 5-1	tong (5 mg if feat	Noted on Noted In Street of Street o	segulation studies if liver function bnormal or there are concerns	 Fluid restriction (replace) bits and then 80-45 nm 	loss at Tour	Hydrolasine 5-12 mo 15 mg if troat
	Timing of birth			 Spot un Pre-ect 	ine PUR ampsia bloods + coaquiation b	ooth 1	John Mannis Planas	expectant approach. Chear plan de	stoped including to	al 721	disampel of page analy-	NE DORE	ible placental abruption	total fluid)	-	compromise) for bolus over 3-
defore 37 weeks: Do not recommend birth unless other contracted or fully indicated as associt if			· Assess	fetal growth jumbilical artery C	unith jumbilical artery Coppler asset Offenon		n monitoring ant meanods, to pain term if condition of womaniperson or faiture intercostee. If indication for bettli presents, administer contrastenade for Multi-tur		Onext: 22 minutes Ropest		Fotol much				Orset 20 minutes Repeat	
- After 17 weater for any and a second commonly with a loss data of							maturation and magnetium subplate for Matineuroprotection (F <30 weeks). No required F elready on magnetium subplate. Consider impetient memagement.			4 Maximum: 30 mg (consider IV)		A guidelines for management if di	annoad		every 22 minutes Maximum: 33 min (consider 17	
adverse subcomes, consider espectant management beyond 37					Treatment		 At 34+0 to 34+5 exerts: Plan an expectant approach. Offer induction of labor- material or latel indications as even delears: has long 71 Consider inselant. 			I want of orgeneided had before		ar assessment of time of discovers do not		2 Concept concells, 195% in. 27 manufes		balus of crystalloid fluid before
weeks with in	creased receilaring			 Cnity co Begin r 	inclusive breaknent is bith of 5 represents subphate - see prof	iby and place	After 37 weeks (e.g. 37+5	E Recomment birth. No approciable	benefit in con				Eclampsia			by dratazine date, usually 200-
	Introortum			+ Statler	thypertensive (acute), eim for	e target BP I	loan d'cald regilite he	c the sense of the set			New onse	et of seizu	res in association with pre-eclam	psia		300 mL)
· At least hours	a BR in block			Maternal monitoring Materna					r		AL O	Segnosis Antihumertensives fo		Antihyperlensives far	•	
· Costinue authorations				• Marap	ement plan should include			Introperture		Energe	Emergency transfer of care to obeautric te		efertal code 4006)	40 to gettework stude	n	Magnesium sulphate
				Their Lb	ion with the womaniperson, IC, obesitric, anawathetic and	Bisod during	Continue antihypertensives - adjust if necessary for other factors, e.g. nex			natope	-mediate airway, breathing, sinulation, di anagement		ity, exposure (ABCOE)	Labelaiki Initialiy 20 mp IV bekis over 2 minutes	2	seizures, this anticonvulsant
Bastanton				interety	interative care teams and physicians mainle propriets a Please		Flad balance monitoring			 BP control of primary importance if a listed to present exclusion health; 		pevone				medicine should be administered - see protocol
+ If an reality	etty Gestational hypertension			tally pre-eclampsia bloods in Baai						Pre-eclampois bloods * coepulation		rioth		Repeat with 40-80 mg Onset 5 minutes Report eith	ne	
anthyperte	(New onset of hypertension after 20 weeks)	gestatic	on without signs of		irms about possible placental	tel - Fluid r deliver	Peniparkan • Eon methylopa, consider changing to another antihypertensive, eg. ACE binkelar			indicated	Rasess felal growth (ambilical artery Dog indicated) Travater		seasoners are careotocography r	40-80 mg Repeat: every 10 minutes Maximum: 300 mg	#Y	Pre-eclampsis bloods
< BP at home	pre-ecompeas and doin 250 pr at	37 2143	mmingi													+ FBC
then approx	At discussion		Erest ite				 Advise to stay in seconds 	eyhortiary facility for at least 72 hou	ta (4-6 hours)	Only conclusive treatment is birth of #		the beby b	ut aim to stabilize and monitor if	Nifedgine"		Creatinine
a Monobel to	A Gage Sea		antibuterter	u abaa	Petarno		 DP at home 24-hour poet transafter in ing with ner 	> at home 24-hour post discharge, then at one week, then approximately anader in line with near increase planning according to BP stability and		Begin ru	Jonesene a 1.or neenik' postalion Begin magnesium sulphale - see prob			reinase capeules)	5	+ LFT (rel AST, ALT)
comprehen	Pre-estampsis bloods	- Laberarial			situatus Pragmatus subhits rum Tening of bi oni age: Recommend time affects of construction (2014) washed, and m tion (21-32 washed, has been complex manufacture subhits		condition senarity	CH and LMC a commission do		 If hypertensive, start antihypertensive 		w, aim for a target BP below 140/100 mm/Hg		Repeat: after 30-45 minutes		 Cosputition If Ap1, AL1 abnormation plateters
	Prompt informal to obtaining cases referred code 48283 Assess traiting provid/versilineing (CEE, unablicational antery Dapplan assessment and and (CE) for indication() Consister initiating find line antihygentensions		· Atlasipina				· Consider 5-week abalahi	t rolev			Maternal membering One-to-one midelifery care Management plan should include discussion with the anaesthetic and		Maternal maniforing - magnesium sulphate	Hastmurk 83 mg daily Hydrolatine		
			 Methyloopa 				* Early manifest being other union of	which is contributed with manufacture which	a feasible	One-to-c Material						Signs and symptoms of
							me permite) - noi required if	LFT (INLAST, ACT) Consulation EAST, BUT		decursi			during bolus does, then hourly	compromise (// bolus over 3-		pre-eclampsia
	 Decase any symptoms of pre-eclempsis with the womanipert their family. 	ion and	Pre-eclampela	bloods				abromallow plateets		lead	CARL NUME OF AND AND OF		during maintenance dose • Respiratory rate, C2 saturation,	12 minutes Onext, 23 minutes Repeat	1.	Severe headache Visual dishcharcus
	Notes and an advantage		- FEC		INF excellence for example	parken men h-11 m	enders i la linderna i il con			Pourly 8	8 ^a and ranginatory naise lances inhord		reflexes hourly	every 20 minutes Maximum, 33 pp Vocaldar M	5	 Severe epipestric pain
	Marriel mensaring		- Decession		en suphata - follow protocol			Signs and symptoms of		Atlanti	dely pre-oriempela bloods		hours)	bolus of crystalloid fluid before		 Shothess of breath Release and an annual second secon
	monitoring in decussion with the womaniperson and their LMC		- UFT (red AST, A)	LT) antihgertemives - adje		necessary for	other factors, for example,	Severs headache		tests and	abnormal or there are conc	20710	bith and then 80-85 mL/hour	hydratazine dase, usually 200	- []	Nausea, vomiting
	Carry sut BP and sine diputick for protein weekly	. Г	Cosputation # A5 absorball low off	1, 611	hagneours subhate, reartso	a anaosthesi		Visual disturbances		mentil pi	resore passerial abruption		1068 1040)	And and		 budden swelling of face, hands, or feet
	Pladebindease in Bir or ree patiential, or other signs of pro- obligations, co pro-other post block and PCR Petal monthoring Fallar Falla							servers sygnitic pan siturities of breath			Fetal mr		10			Hyperrefexia
			Shares and sure	there of	magnesium sulphate for 24	0.0		Rebistenal pressure/pain Neuses, vomiting		 CTG continuous if magnesium sulph 		hala running)		Magnesium sulphate		ran peripasi seven hijisteraka.
			pre-eclare	pala	hyldopa, consider changing t	another anti-	ypertensive, for example,	- Sudden swelling of face.			Time	ne of birth		seizures, this anticonvulsant		
	- works URL APV, with any Support and CTS FinishersT - Borry Testing of the Support and Suppo				to monitor for disease reads	tion, States an	hypertensives as required	- Hypenefecia	1 2	Any pestational age: Recomment birth a		afar sooli	sing the womaniperson and a	metione should be administered - see protocol		
					 stay in secondary/tertiary to the 24 hours post discharge. 	any for at least best at one we	If 72 hours (4–4 hoursy BP) ees, then approximately according to server(h) according to server(h)			ourse in concentendo (* 13448 weeks) europrotection (f <32 weeks) has been deady on magnesium subhate		(a) and magnetium sulphate for in sampleded (if time permitte) —not required if				
				pen .	ersafer (in line with case-by	case planning								Pro-oclampsia bloods		
				autopain.							Introporture		an in	Electrolides		
					end traveck ubstatic revew					 Proguest 8P monitoring (eg. every 1 sulphate – failure protocal 		1-15 minutes) in labour, If on magnesium		Coatrine		
				and and any mapping resonance and appendix any fills. To contrador of which an prophets sense hypothesis					Coldnuous CTG Continues anthogeneratives - articular effect of magnesium sulphate, neuros		ual Fracessary for other ladors, for example, scrucial associations Peolpartum		LPT (sol AST, ALT) Coapdation PAST, ALT almormal/our platelets			
	Introportum - Hypertelixia															
	aasthoury S* is labour									Per						
	 Continue antihyperfermions - adjust if recessary for other has exempte, recessed anaeothesis 	wheters for Antihypertensives and								Continue magnesium subshate for 3		It fount		Signs and symptoms of pre-oclampsia • Zevere headache		
	Postpartam - Culorito Hospita			ling					ACE intom		ana gyarana ya Katalala,					
				vering if	at .					Continue to monitor for disease read Advise to siles in secondary/brillery/it			te antihypertensives as required Eleast 72 hours (4-6 hourly 8P)	Severe epigestric pain		
	example, ACE inhibitor	~~	Orange to compa	624						BP at he would be	ana 24 hours post dacharge Perceber (in ina with range)	Daniel of	to week, then approximately prote according to Bill stability and	Shotness of breath Detroitement Interviewence		
	- DP at home 34 hours post discharge, then at one week, then		example. ADE Int	side of						condition	serverb)		and a second of the state of the	Nausea, vombing		
	according to BP stability and condition severity)		Wary pro-bern hall house an increases	ins may						NO4DER	to send the womaniperson's Y	COP and C	M: a canprenervo discharge	 Sudden swelling of face, hands, or feet. 		
	 Hospital to send the womaniperson's GP and LWC a compret declarate summary 	eviane	adverse effects b						L.	Record	nend 6-week obstablic ravies			Hypersteals		

For more information on preterm preeclampsia including access to Taonga Tuku Iho (national best practice guide), you can access the Carosika Collaborative website **www.carosikacollaborative.co.nz** or by using the QR code.





Risk assessment & management for the prevention of preeclampsia

Assessment made at booking



Major risk factors (relative risk/odds ratio >3)

- Antiphospholipid syndrome
- Systemic lupus erythematosus
- Previous preeclampsia
- Assisted reproductive technology therapy with oocyte donation
- Renal disease
- Chronic/pre-existing hypertension
- Previous HELLP syndrome
- Pre-existing diabetes
- Family history (mother or sibling) with preeclampsia

Wāhine/people with ≥1 major risk factor

Recommend and prescribe **aspirin** Daily 100 mg oral dose taken at night/evening, commenced between 12⁺⁰ to 20⁺⁰ weeks, and continued to 36⁺⁰ weeks

Consider calcium supplementation

(particularly for those with low dietary intake of calcium) Daily 1.5-2.0g oral dose from booking to birth

Other risk factors (relative risk/odds ratio ≤3)

- Nulliparity
- Multiple pregnancy
- Other family history of preeclampsia
- Father of baby born via pregnancy with preeclampsia
- Ethnic group Māori, Pacific Peoples, Indian, African
- New paternity in current pregnancy
- BMI ≥35 kg/m² (pre-pregnancy or early in pregnancy)
- Pregnancy interval >10 years
- Wāhine/person age ≥40 years
- Assisted reproductive technology therapy with sperm donation
- Any assisted reproductive technology therapy
- dBP ≥80 mmHg at booking





Pre-existing/chronic hypertension

Hypertension confirmed preconception or before 20 weeks gestation

First visit in pregnancy

- Change ACE inhibitor/ARB to alternative antihypertensive
- Assess for other risk factors for preeclampsia
- Prescribe calcium 1.5 2.0g daily
- Prescribe aspirin 100mg nocte at 12⁺⁰–16⁺⁶ weeks gestation
- Refer to obstetric team (Consultation referral code 1014)
 Educate wahine/person and whānau about signs and symptoms of preeclampsia

Maternal monitoring

- Baseline urine microscopy & PCR, preeclampsia blood tests
- Maintain usual schedule of antenatal visits, but individualise frequency of BP monitoring & monitor more closely if unstable
- Aim to control hypertension sBP ≤135 and dBP ≤85 mmHg
- Repeat urine PCR, preeclampsia blood tests in the event of a rise in BP, new proteinuria and/or other signs & symptoms of preeclampsia
- Arrange a same-day referral back to the obstetric team if preeclampsia develops (Consultation referral code 4022)

Fetal monitoring

- Arrange a monthly USS for fetal growth from 24-26 weeks
- If FGR occurs, follow the Te Whatu Ora SGA and FGR clinical practice guideline and the Carosika Management of preterm FGR/SGA (<37⁺⁰ weeks) Algorithm

Timing of birth

- <37⁺⁰ weeks: do not recommend planned preterm birth unless other māmā/person and/or pēpi indications
- ≥37⁺⁰ weeks (and <40⁺⁰ weeks): for wāhine/people with a low risk of adverse outcomes, consider expectant management beyond 37 weeks with increased monitoring

Intrapartum

- At least hourly BP in labour
- Continue antihypertensives, adjust as required, e.g. regional anaesthesia

Postpartum

- Consider changing to an alternative antihypertensive e.g. ACE inhibitor
- BP monitoring at home with case-by-case planning according to BP stability and condition severity e.g. 24 hours post-discharge, one week, and then approximately weekly
- Comprehensive hospital discharge summary to wahine/ person's primary care provider and LMC

Adapted from: Te Whatu Ora – Health New Zealand. 2022. Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aotearoa New Zealand: Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa: A clinical practice guideline

First-line antihypertensives

- Labetalol
- Nifedipine
- Methyldopa
- Frequency/dosing titrated to BP

Preeclampsia blood tests

- FBC (platelets)
- Electrolytes & creatinine
- LFT (incl AST, ALT)
- Coagulation studies if high AST/ALT or low platelets

Signs & symptoms of preeclampsia

- Severe headache
- Visual disturbance
- Severe epigastric pain
- Shortness of breath
- Retrosternal pressure/pain
- Nausea, vomiting
- Sudden swelling of face, hands or feet
- Hyperreflexia

Abbreviations:

- ACE angiotensin converting enzyme
- ARB angiotensin receptor blocker
- ALT alanine transaminase
- AST aspartate transaminase BP - blood pressure
- BP DIOOO pressure dPD - digstolia blood pi
- dBP diastolic blood pressure CTG - cardiotocograph
- FBC full blood count
- FGR fetal growth restriction
- IV intravenous
- LFT liver function test
- LMC lead maternity carer
- PCR protein:creatinine ratio
- sBP systolic blood pressure SGA - small for gestational age
- USS ultrasound scan



Gestational hypertension

New onset hypertension (sBP ≥140 mmHg or dBP ≥90) after 20 weeks gestation without signs of preeclampsia

At diagnosis

- Urine PCR and preeclampsia blood tests
- Refer to obstetric team (Consultation referral code 4009)
- Arrange an USS to assess fetal growth
- Consider antihypertensives if sBP ≥140 and/or dBP ≥90 mm Hg
- Educate wahine/person & whānau about signs and symptoms of preeclampsia

Maternal monitoring

- Obstetric team makes an assessment plan for ongoing care and monitoring in consultation with wahine/person and LMC
- Weekly BP and urine protein dipstick
- Aim to control hypertension sBP ≤135 and dBP ≤85 mmHg
- Repeat urine PCR, preeclampsia blood tests in the event of a rise in BP, new proteinuria and/or other signs & symptoms of preeclampsia
- Arrange a same-day referral back to obstetric team is
 preeclampsia develops (Consultation referral code 4022)

Fetal monitoring

- Arrange a monthly USS for fetal growth from time of diagnosis
- If FGR occurs, follow the Te Whatu Ora SGA and FGR clinical practice guideline and the Carosika Management of preterm FGR/SGA (<37⁺⁰ weeks) Algorithm

Timing of birth

- <37⁺⁰ weeks: do not recommend planned preterm birth unless other māmā/person and/or pēpi indications
- 237⁺⁰ and <40⁺⁰ weeks: consider expectant management or planned birth in discussion with wahine/person and their LMC

Intrapartum

- At least hourly BP in labour
- Continue antihypertensives, adjust as required, e.g. regional anaesthesia

Postpartum

- Consider changing to an alternative antihypertensive e.g. ACE inhibitor
- BP monitoring at home with case-by-case planning according to BP stability and condition severity e.g. 24 hours post-discharge, one week, and then approximately weekly
- Comprehensive hospital discharge summary to wahine/ person's primary care provider and LMC

Adapted from: Te Whatu Ora – Health New Zealand. 2022. Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aotearoa New Zealand: Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa: A clinical practice guideline

First-line antihypertensives

- Labetalol
- Nifedipine
- Methyldopa
- Frequency/dosing titrated to BP

Preeclampsia blood tests

- FBC (platelets)
- Electrolytes & creatinine
- LFT (incl AST, ALT)
- Coagulation studies if high AST/ALT or low platelets

Signs & symptoms of preeclampsia

- Severe headache
- Visual disturbance
- Severe epigastric pain
- Shortness of breath
- Retrosternal pressure/pain
- Nausea, vomiting
- Sudden swelling of face, hands or feet
- Hyperreflexia

Antihypertensives & breastfeeding

- Establish breastfeeding if this is planned
- Ensure a compatible antihypertensive, e.g. ACE inhibitor
- Very preterm babies may have an increased risk of adverse effects from antihypertensives



Preeclampsia

New onset hypertension (dBP ≥90 mmHg or sBP ≥140 mmHg) after 20 weeks gestation with proteinuria and/or māmā/person organ dysfunction and/or uteroplacental dysfunction (see definitions)

At diagnosis

- Same-day referral to obstetric team (Consultation referral code 4022)
- Urine PCR and preeclampsia blood tests
- Arrange an USS to assess fetal growth
- Consider antihypertensives if sBP ≥140 and/or dBP ≥90 mm Hg
- Aim to control hypertension sBP ≤135 and dBP ≤85 mmHg
- Educate wahine/person and whānau about signs and symptoms of worsening preeclampsia

Maternal monitoring

- Obstetric team makes an assessment plan for ongoing care and monitoring in consultation with wahine/person and LMC which should initially include hospital admission
- BP 4-6 hourly (except overnight when an interval of 8 hours is acceptable)
- Repeat preeclampsia blood tests at least weekly (coagulation studies if high AST/ALT, low platelets or concerns for placental abruption)

Fetal monitoring

- Arrange a monthly USS for fetal growth from time of diagnosis
- If FGR occurs, follow the Te Whatu Ora SGA and FGR clinical practice guideline and the Carosika Management of preterm FGR/SGA (<37⁺⁰ weeks) Algorithm
- Daily CTG if inpatient (computerised CTG if available)

Timing of birth and preparation for preterm birth

- <34⁺⁰ weeks: Plan an expectant approach with a clear plan including consideration of *in utero* transfer and level of monitoring and thresholds to plan birth if condition of wahine/person and/or pēpi deteriorates
- 34⁺⁰ to 36⁺⁶ weeks: Discuss the risks and benefits of planned vs expectant management. Recommend an expectant approach unless features of severe preeclampsia or evidence of pēpi compromise
- 237⁺0 weeks: Recommend birth as no appreciable benefit in continuing pregnancy. Wahine/person, LMC and obstetric team agree timing & mode
- **Preterm birth**: If indication for planned preterm birth presents, administer corticosteroids if ≤34⁺⁶ weeks and magnesium sulphate for fetal neuroprotection if <30 weeks. Preeclampsia alone is not an indication for caesarean section regardless of gestation

Intrapartum

- At least hourly BP in labour
- Continue antihypertensives, adjust as required, e.g. regional anaesthesia
- Fluid balance monitoring
- · Recommend placental histological examination for preterm preeclampsia

Postpartum

- Consider changing to an alternative antihypertensive e.g. ACE inhibitor
- BP monitoring 4–6 hourly and titrate antihypertensives as required
- Monitor for disease resolution, stay in secondary/tertiary facility for ≥72 hours
- BP monitoring at home with case-by-case planning according to BP stability and condition severity e.g. 24 hours post-discharge, one week, and then approximately weekly
- Test for antiphospholipid syndrome if preterm birth <34⁺⁰ weeks
- Provide individualised counselling on the chance of recurrence and longerterm health implications
- Comprehensive hospital discharge summary to wahine/person's primary care provider and LMC

Adapted from: Te Whatu Ora – Health New Zealand. 2022. Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aotearoa New Zealand: Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa: A clinical practice guideline

First-line antihypertensives

- Labetalol
- Nifedipine
- Methyldopa
 - Frequency/dosing titrated to BP

Antihypertensives for acute lowering of BP

IV Labetalol

- Initial: 20 mg bolus over 2 mins
- Onset: 5 mins
- Repeat: every 10 mins with 40– 80mg (if needed)
- Maximum: 300 mg

Nifedipine

- Initial: 10 mg (immediate release capsules)
- Onset: 30–45 minutes
- Repeat: 10mg after 30–45 minutes (if needed)

• Maximum: 80 mg daily Take care using with magnesium sulphate, risk of severe hypotension

IV Hydralazine

- 5-10 mg bolus (5 mg if concern of pēpi compromise) over 3-10 mins
 Opent: 20 mins
- Onset: 20 mins
- Repeat: 5-10mg every 20 mins
- Maximum: 30 mg

Consider IV bolus 200–300 mL crystalloid fluid before/with first dose

Preeclampsia blood tests

- FBC (platelets)
- Electrolytes & areatinine
- LFT (incl AST, ALT)
- Coagulation studies if high AST/ALT or low platelets

- Severe headache
- Visual disturbance
- Severe epigastric pain
- Shortness of breath
- Retrosternal pressure/pain
- Nausea, vomiting
- Sudden swelling of face, hands or feet
- Hyperreflexia



Severe/unstable preeclampsia

(see definitions)

At diagnosis

- Same-day referral to obstetric team (Consultation referral code 4022)
- Admit to secondary or tertiary facility
- Commence antihypertensives therapy and aim to control hypertension sBP <135 and dBP <85 mmHq
- Urgently treat severe hypertension, sBP ≥160 mmHg* and/or dBP ≥110 mmHg
- Urine PCR and preeclampsia blood tests
- Arrange an USS to assess fetal growth
- Consider need for IV magnesium sulphate to prevent an eclamptic seizure

Maternal monitoring

- One-to-one midwifery care
- Obstetric led management including anaesthesia and intensive care
- Hourly BP and respiratory rate
- Fluid balance chart
- At least daily preeclampsia bloods (coagulation studies if high AST/ALT, low platelets or concerns for placental abruption)

Maternal monitoring – magnesium sulphate

- BP every 5 mins during bolus dose, hourly with maintenance dose
- Respiratory rate, O₂ saturation, reflexes hourly
- Urine output (>100 mL over 4 hours)
- Fluid restriction (80–85 mL/hour total fluid)

Fetal monitoring

- If FGR present, follow the Te Whatu Ora SGA/FGR clinical practice guideline and the Carosika Management of preterm FGR/SGA (<37⁺⁰ weeks) Algorithm
 Daily CTG (computerised if available and continuous if magnesium sulphate is given)
- Dairy CTG (computerised if available and continuous if magnesium sulphate is

Timing of birth and preparation for preterm birth

- <22⁺⁰ and 22⁺⁰-24⁺⁶ weeks: Manage in tertiary unit with maternal fetal medicine involvement, careful discussion with wahine/person & whānau
- <34⁺⁰ weeks: Adopt expectant approach with *in utero* transfer for care in a secondary/tertiary unit with resources for māmā/person and pēpi monitoring and critical care
- 34⁺⁰-36⁺⁶ weeks: Recommend planned birth unless the only feature of severe preeclampsia is FGR with oligohydramnios/abnormal Doppler (follow Carosika Management of preterm FGR/SGA (<37⁺⁰ weeks) Algorithm)
- 237⁺⁰ weeks: Recommend birth after stabilising in a centre with appropriate resources for care of the wahine/person and pēpi
- **Preterm birth**: If indication for planned preterm birth presents, administer corticosteroids if ≤34⁺⁶ weeks and magnesium sulphate for fetal neuroprotection if <30 weeks. Preeclampsia alone is not an indication for caesarean section regardless of gestation

Intrapartum

- At least hourly BP in labour
- · Continue antihypertensives, adjust as required, e.g. regional anaesthesia
- Fluid balance monitoring
- Recommend placental histological examination for preterm preeclampsia

Postpartum

- Continue magnesium sulphate for ≥24 hours if used for maternal indications
- Consider changing to an alternative antihypertensive e.g. ACE inhibitor
- BP monitoring 4–6 hourly and titrate antihypertensives as required
- Monitor for disease resolution, stay in secondary/tertiary facility for ≥72 hrs
- BP monitoring at home with case-by-case planning according to BP stability and condition severity e.g. 24 hours post-discharge, one week, and then approximately weekly
- Test for antiphospholipid syndrome if preterm birth <34⁺⁰ weeks
- Provide individualised counselling on the chance of recurrence and longerterm health implications
- Comprehensive hospital discharge summary to wahine/person's primary care provider and LMC

Adapted from: Te Whatu Ora – Health New Zealand. 2022. Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aotearoa New Zealand: Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa: A clinical practice guideline

*Antihypertensives for acute lowering of BP

IV Labetalol

- Initial: 20 mg bolus over 2 mins
 Onset: 5 mins
- Repeat: every 10 mins with 40-80mg (if needed)
- Maximum: 300 mg

Nifedipine

- Initial: 10 mg (immediate release capsules)
- Onset: 30–45 minutes
- Repeat: 10mg after 30–45 minutes (if needed)
- Maximum: 80 mg daily Take care using with magnesium sulphate, risk of severe hypotension

IV Hydralazine

- 5–10 mg bolus (5 mg if concern of pēpi compromise) over 3–10 mins
- Onset: 20 mins
- Repeat: 5-10mg every 20 mins
- Maximum: 30 mg

Consider IV bolus 200–300 mL crystalloid fluid before/with first dose

Magnesium sulphate

To prevent eclamptic seizure, magnesium sulphate is the anticonvulsant medicine of choice – see protocol for use as indicated

Preeclampsia blood tests

- FBC (platelets)
- Electrolytes & areatinine
- LFT (incl AST, ALT)
- Coagulation studies if high AST/ALT or low platelets

- Severe headache
- Visual disturbance
- Severe epigastric pain
- Shortness of breath
- Retrosternal pressure/pain
- Nausea, vomiting
- Sudden swelling of face, hands or feet
- Hyperreflexia



Eclampsia

New onset of seizures in association with preeclampsia

At diagnosis

- Immediate airway, breathing, circulation, disability, exposure (ABCDE) care
- Emergency transfer of responsibility and care to obstetric team (Consultation referral code 4006)
- Admit to hospital and consider transfer to secondary/tertiary facility
- Urine PCR and preeclampsia blood tests
- CTG to assess fetal wellbeing (computerised if available)

Treatment

- Stabilise whilst monitoring and making plan for birth
- Commence IV magnesium sulphate to prevent further eclamptic seizures
- Commence antihypertensive therapy and aim to control hypertension sBP <135 and dBP <85 mmHg
- Urgently treat severe hypertension, sBP ≥160 mmHg* and/or dBP ≥110 mmHg

Maternal monitoring

- One-to-one midwifery care
 Obstetric led management
- including anaesthesia and intensive careHourly BP and respiratory rate
- Fluid balance chart
- At least daily preeclampsia bloods (coagulation studies if high AST/ALT, low platelets or concerns for placental abruption)

Maternal monitoring – magnesium sulphate

- BP every 5 mins during bolus dose, hourly with maintenance dose
- Respiratory rate, O₂ saturation, reflexes hourly
- Urine output (>100 mL over 4 hours)
- Fluid restriction (80–85 mL/hour total fluid)

Fetal monitoring

CTG (computerised if available and continuous whilst magnesium sulphate is given)

Timing of birth and preparation for preterm birth

Any gestational age: Recommend birth after stabilisation of wahine/person. If time permits, *in utero* transfer for birth in a secondary/tertiary unit with resources for māmā/person and pēpi monitoring and critical care

Preterm birth: Administer corticosteroids if ≤34⁺⁶ weeks but do not delay birth if detrimental to immediate health of wahine/person and/or pēpi. Additional magnesium sulphate is not required. Preeclampsia alone is not an indication for caesarean section regardless of gestation

Intrapartum

- Frequent BP monitoring in labour
- Continuous CTG monitoring
- · Continue antihypertensives, adjust as required, e.g. regional anaesthesia

Postpartum

- Continue magnesium sulphate for ≥24 hours
- Consider changing to an alternative antihypertensive e.g. ACE inhibitor
- BP monitoring 4–6 hourly and titrate antihypertensives as required
- Monitor for disease resolution, stay in secondary/tertiary facility for ≥72 hrs
 BP monitoring at home with case-by-case planning according to BP stability and condition severity e.g. 24 hours post-discharge, one week, and then approximately weekly
- Provide individualised counselling on the chance of recurrence and longerterm health implications
- Comprehensive hospital discharge summary to wahine/person's primary care provider and LMC

Adapted from: Te Whatu Ora – Health New Zealand. 2022. Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aotearoa New Zealand: Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa: A clinical practice guideline

*Antihypertensives for acute lowering of BP

IV Labetalol

- Initial: 20 mg bolus over 2 mins
- Onset: 5 mins
- Repeat: every 10 mins with 40-80mg (if needed)
- Maximum: 300 mg

Nifedipine

- Initial: 10 mg (immediate release capsules)
- Onset: 30–45 minutes
- Repeat: 10mg after 30-45
 minutes (if needed)

• Maximum: 80 mg daily Take care using with magnesium sulphate, risk of severe hypotension

IV Hydralazine

- 5–10 mg bolus (5 mg if concern of pēpi compromise) over 3–10 mins
- Onset: 20 mins
- Repeat: 5-10mg every 20 mins
- Maximum: 30 mg

Consider IV bolus 200–300 mL crystalloid fluid before/with first dose

Magnesium sulphate

To prevent eclamptic seizure, magnesium sulphate is the anticonvulsant medicine of choice – see protocol for use as indicated

Preeclampsia blood tests

- FBC (platelets)
- Electrolytes & areatinine
- LFT (incl AST, ALT)
- Coagulation studies if high AST/ALT or low platelets

- Severe headache
- Visual disturbance
- Severe epigastric pain
- Shortness of breath
- Retrosternal pressure/pain
- Nausea, vomiting
- Sudden swelling of face, hands or feet
- Hyperreflexia



HELLP

A variant of severe pre-eclampsia including Haemolysis, Elevated Liver enzymes and Low Platelet count

At diagnosis

- Emergency transfer of responsibility and care to obstetric team (Consultation referral code 4006)
- Admit to hospital and consider transfer to secondary/tertiary facility
- Urgently treat severe hypertension, sBP ≥160 mmHg* and/or dBP ≥110 mmHg
- Urine PCR and preeclampsia blood tests
- CTG to assess fetal wellbeing (computerised if available)
- Arrange an USS to assess fetal growth

Treatment

- Stabilise whilst monitoring and making plan for birth
- Consider IV magnesium sulphate to prevent eclamptic seizure
- Commence antihypertensives therapy and aim to control hypertension sBP ≤135 and dBP ≤85 mmHg
- Urgently treat severe hypertension, sBP ≥160 mmHg* and/or dBP ≥110 mmHg

Maternal monitoring

- Obstetric led management including anaesthesia and intensive care
- Hourly BP and respiratory rate
- Fluid balance chart
- At least daily preeclampsia bloods including coagulation studies

Maternal monitoring – magnesium sulphate

- BP every 5 mins during bolus dose, hourly with maintenance dose
- Respiratory rate, O₂ saturation, reflexes hourly
- Urine output (>100 mL over 4 hours)
- Fluid restriction (80–85 mL/hour total fluid)

Fetal monitoring

• CTG (computerised if available and continuous whilst magnesium sulphate is given)

Timing of birth and preparation for preterm birth

Any gestational age: Recommend birth after stabilisation of wahine/person. If time permits, *in utero* transfer for birth in a secondary/tertiary unit with resources for māmā/person and pēpi monitoring and critical care

Preterm birth: Administer corticosteroids if ≤34⁺⁶ weeks and magnesium sulphate if <30 weeks (if not already given), but do not delay birth if detrimental to immediate health of wahine/person and/or pēpi. Preeclampsia alone is not an indication for caesarean section regardless of gestation

Intrapartum

- At least hourly BP in labour
- Continuous CTG monitoring
- Continue antihypertensives, adjust as required, e.g. regional anaesthesia

Postpartum

- Continue magnesium sulphate for ≥24 hours if used for maternal indications
- Consider changing to an alternative antihypertensive e.g. ACE inhibitor
- BP monitoring 4–6 hourly and titrate antihypertensives as required
- Monitor for disease resolution, stay in secondary/tertiary facility for ≥72 hrs
 BP monitoring at home with case-by-case planning according to BP stability and condition severity e.g. 24 hours post-discharge, one week, and then approximately weekly
- Provide individualised counselling on the chance of recurrence and longerterm health implications
- Comprehensive hospital discharge summary to wahine/person's primary care provider and LMC

Adapted from: Te Whatu Ora – Health New Zealand. 2022. Diagnosis and Treatment of Hypertension and Preeclampsia in Pregnancy in Aotearoa New Zealand: Te Tautohu, Te Tumahu i te Toto Pōrutu me te Pēhanga Toto Kaha i te Hapūtanga ki Aotearoa: A clinical practice guideline

*Antihypertensives for acute lowering of BP

IV Labetalol

- Initial: 20 mg bolus over 2 mins
- Onset: 5 mins
- Repeat: every 10 mins with 40-80mg (if needed)
- Maximum: 300 mg

Nifedipine

- Initial: 10 mg (immediate release capsules)
- Onset: 30–45 minutes
- Repeat: 10mg after 30-45
 minutes (if needed)

• Maximum: 80 mg daily Take care using with magnesium sulphate, risk of severe hypotension

IV Hydralazine

- 5–10 mg bolus (5 mg if concern of pēpi compromise) over 3–10 mins
 Onset: 20 mins
- Penegt: 5-10mg overv 20 m
- Repeat: 5-10mg every 20 mins
- Maximum: 30 mg Consider IV bolus 200–300 mL

crystalloid fluid before/with first dose

Magnesium sulphate

To prevent eclamptic seizure, magnesium sulphate is the anticonvulsant medicine of choice – see protocol for use as indicated

Preeclampsia blood tests

- FBC (platelets)
- Electrolytes & areatinine
- LFT (incl AST, ALT)
- Coagulation studies if high AST/ALT or low platelets

- Severe headache
- Visual disturbance
- Severe epigastric pain
- Shortness of breath
- Retrosternal pressure/pain
- Nausea, vomiting
- Sudden swelling of face, hands or feet
- Hyperreflexia

